- ProCyte has begun a Phase II trial of Tricomin (PC1358) for male pattern baldness. In the study, expected to enroll 36 men with early-stage androgenic alopecia, the peptide-copper compound will be applied topically twice daily. While the specific mechanism of action of the compound is not known, in vivo and in vitro studies have demonstrated this class of compounds to be pharmacologically-active in stimulating and protecting hair follicles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze